CDK 4/6 inhibitors

What are CDK 4/6 inhibitors?

CDK4/6 inhibitors are a class of drugs that target particular enzymes, called CDK4 and CDK6. CDK stands for cyclin-dependent kinase, and it is an enzyme that is important for cell division. CDK4/6 inhibitors interrupt signals that stimulate the proliferation of malignant (cancerous) cells.

Certain cancers, for example, hormone receptor-positive breast cancer, are more likely to have disturbances in CDK4/6, and CDK 4/6 inhibitors may form part of the treatment protocol. Most often, CDK4/6 inhibitors are given synergistically with hormonal therapy (such as an aromatase inhibitor or fulvestrant), although the CDK4/6 inhibitor abemaciclib may be used alone to treat hormone receptor-positive, HER2-negative metastatic breast cancer in pre-treated patients.

Research shows CDK4/6 inhibitors increase the time people have before cancer spreads (progression-free survival). Piezzo (2020) also showed a significant improvement in overall survival (OS) for CDK 4/6 inhibitors as a group for both aromatase inhibitor (AI)-sensitive (HR 0.75, 95% CI) and AI-resistant patients (HR 0.77, 95% CI [0.67–0.89]). However, single-drug analysis revealed palbociclib was the only class member not showing a statistically significant HR for OS (HR 0.83, 95% CI [0.68–1.02]).

Common side effects include fatigue and gastrointestinal disturbances, such as nausea, diarrhea, and vomiting. Bone marrow suppression resulting in neutropenia and leukopenia may also occur, although anemia and thrombocytopenia are less common. In general, the side effects associated with CDK4/6 inhibitor therapy are less severe than those experienced with chemotherapy.

 

1. Piezzo, M., Chiodini, P., Riemma, M., Cocco, S., Caputo, R., Cianniello, D., Di Gioia, G., Di Lauro, V., Rella, F. D., Fusco, G., Iodice, G., Nuzzo, F., Pacilio, C., Pensabene, M., & De Laurentiis, M. (2020). Progression-Free Survival and Overall Survival of CDK 4/6 Inhibitors Plus Endocrine Therapy in Metastatic Breast Cancer: A Systematic Review and Meta-Analysis. International journal of molecular sciences, 21(17), 6400. https://doi.org/10.3390/ijms21176400

List drug with CDK 4/6 inhibitors

Drug Name
Abemaciclib
Generic name: Abemaciclib
Ibrance
Generic name: Palbociclib
Kisqali
Generic name: Ribociclib
Kisqali (200 mg daily-dose)
Generic name: Ribociclib
Kisqali (400 mg daily-dose)
Generic name: Ribociclib
Kisqali (600 mg daily-dose)
Generic name: Ribociclib
Palbociclib
Generic name: Palbociclib
Ribociclib
Generic name: Ribociclib
Verzenio
Generic name: Abemaciclib

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords